Eric Coldwell
Stock Analyst at Baird
(4.26)
# 734
Out of 4,479 analysts
106
Total ratings
61.67%
Success rate
11.18%
Average return
Main Sectors:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMI Owens & Minor | Maintains: Neutral | $24 → $20 | $13.02 | +53.61% | 10 | Jun 25, 2024 | |
| ICLR ICON PLC | Maintains: Outperform | $363 → $367 | $316.51 | +15.95% | 11 | May 31, 2024 | |
| FTRE Fortrea Holdings | Upgrades: Outperform | $45 → $36 | $23.86 | +50.88% | 2 | May 14, 2024 | |
| CRL Charles River Laboratories International | Maintains: Outperform | $282 → $270 | $203.24 | +32.85% | 6 | May 10, 2024 | |
| PINC Premier | Maintains: Neutral | $25 → $22 | $18.58 | +18.41% | 4 | May 8, 2024 | |
| MCK McKesson | Maintains: Outperform | $603 → $671 | $586.34 | +14.44% | 9 | May 8, 2024 | |
| IQV IQVIA Holdings | Maintains: Neutral | $254 → $245 | $208.49 | +17.51% | 8 | May 3, 2024 | |
| CAH Cardinal Health | Maintains: Outperform | $134 → $128 | $97.76 | +30.93% | 8 | May 3, 2024 | |
| LH Labcorp Holdings | Maintains: Outperform | $255 → $244 | $203.13 | +20.12% | 7 | Apr 26, 2024 | |
| MEDP Medpace Holdings | Maintains: Outperform | $446 → $454 | $407.24 | +11.48% | 9 | Apr 24, 2024 | |
| CTLT Catalent | Upgrades: Outperform | $45 → $53 | $56.16 | -5.63% | 1 | Nov 16, 2023 | |
| AHCO AdaptHealth | Maintains: Outperform | $20 → $21 | $9.73 | +115.83% | 8 | Jul 13, 2023 | |
| DGX Quest Diagnostics | Maintains: Neutral | $143 → $154 | $137.09 | +12.33% | 2 | Jan 12, 2023 | |
| WBA Walgreens Boots Alliance | Downgrades: Neutral | $51 | $11.58 | +340.41% | 15 | Apr 1, 2022 | |
| FUL H.B. Fuller Company | Maintains: Neutral | n/a | $76.34 | - | 1 | Mar 27, 2020 | |
| CVS CVS Health | Maintains: Neutral | n/a | $58.15 | - | 3 | Mar 27, 2020 | |
| INCR InterCure | Maintains: Outperform | n/a | $2.03 | - | 2 | Nov 10, 2017 |
Owens & Minor
Jun 25, 2024
Maintains: Neutral
Price Target: $24 → $20
Current: $13.02
Upside: +53.61%
ICON PLC
May 31, 2024
Maintains: Outperform
Price Target: $363 → $367
Current: $316.51
Upside: +15.95%
Fortrea Holdings
May 14, 2024
Upgrades: Outperform
Price Target: $45 → $36
Current: $23.86
Upside: +50.88%
Charles River Laboratories International
May 10, 2024
Maintains: Outperform
Price Target: $282 → $270
Current: $203.24
Upside: +32.85%
Premier
May 8, 2024
Maintains: Neutral
Price Target: $25 → $22
Current: $18.58
Upside: +18.41%
McKesson
May 8, 2024
Maintains: Outperform
Price Target: $603 → $671
Current: $586.34
Upside: +14.44%
IQVIA Holdings
May 3, 2024
Maintains: Neutral
Price Target: $254 → $245
Current: $208.49
Upside: +17.51%
Cardinal Health
May 3, 2024
Maintains: Outperform
Price Target: $134 → $128
Current: $97.76
Upside: +30.93%
Labcorp Holdings
Apr 26, 2024
Maintains: Outperform
Price Target: $255 → $244
Current: $203.13
Upside: +20.12%
Medpace Holdings
Apr 24, 2024
Maintains: Outperform
Price Target: $446 → $454
Current: $407.24
Upside: +11.48%
Catalent
Nov 16, 2023
Upgrades: Outperform
Price Target: $45 → $53
Current: $56.16
Upside: -5.63%
AdaptHealth
Jul 13, 2023
Maintains: Outperform
Price Target: $20 → $21
Current: $9.73
Upside: +115.83%
Quest Diagnostics
Jan 12, 2023
Maintains: Neutral
Price Target: $143 → $154
Current: $137.09
Upside: +12.33%
Walgreens Boots Alliance
Apr 1, 2022
Downgrades: Neutral
Price Target: $51
Current: $11.58
Upside: +340.41%
H.B. Fuller Company
Mar 27, 2020
Maintains: Neutral
Price Target: n/a
Current: $76.34
Upside: -
CVS Health
Mar 27, 2020
Maintains: Neutral
Price Target: n/a
Current: $58.15
Upside: -
InterCure
Nov 10, 2017
Maintains: Outperform
Price Target: n/a
Current: $2.03
Upside: -